ACTRN12611000002987
Not yet recruiting
Phase 4
An open-label, pilot study to examine the pharmacokinetics, efficacy and safety of Methylnaltrexone Bromide in paediatric patients with opioid-induced constipation who have failed standard aperient treatment.
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Opioid-induced Constipation
- Sponsor
- The Royal Children's Hospital
- Enrollment
- 6
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •An inpatient at the Royal Children's Hospital
- •Diagnosis of constipation as defined by lack of bowel motion for 3 days
- •Chronic opioid treatment (1 week continuous duration)
- •Failed all other standard aperient treatment
- •Vascular access
Exclusion Criteria
- •Other causes of constipation (eg cow's milk protein intolerance, poor oral intake)
- •Signs and symptoms of bowel obstruction
- •Suspected or diagnosed with delirium
- •Likely to pass away this admission
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 1
An Open Label, Phase 1 Study evaluating pharmacokinetics, safety and tolerability of ABT-869 in Subjects with Solid tumorssolid tumorsJPRN-jRCT2080220594Abbott Japan Co., Ltd.
Active, not recruiting
Not Applicable
An open – label clinical trial to study pharmacokinetics (PK) of different levels (0.125 mg, 0,25 mg, 0.5 mg) of pramipexole taken once a day by month in children who can accepte stable pramipesole doses for the treatment of Restless Leg Syndrome (RLS) – A disorder which feel the urge to move the legs to reduce the unpleasant sensatioRestless Legs SyndromeMedDRA version: 14.0Level: PTClassification code 10058920Term: Restless legs syndromeSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2011-002774-23-Outside-EU/EEABoehringer Ingelheim Pharmaceuticals, Inc.36
Active, not recruiting
Phase 1
Phase I/II study of avelumab in pediatric cancer subjectsSolid tumors (including central nervous system tumors) and lymphomaMedDRA version: 20.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10025632Term: Malignant lymphomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-002985-28-BEMerck KGaA148
Active, not recruiting
Phase 1
Phase I/II study of avelumab in pediatric cancer subjectsSolid tumors (including central nervous system tumors) and lymphomaMedDRA version: 21.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10025632Term: Malignant lymphomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-002985-28-DKMerck KGaA148
Withdrawn
Not Applicable
A phase I, open-label study to assess the pharmacokinetic profile, safety and tolerability of OBE001 after a single oral administration in pregnant women with medically indicated pregnancy terminatioNA (healthy volunteers)10010273NL-OMON40897ObsEva SA6